Ewing, NJ – According to filings with the U.S. Securities and Exchange Commission, Orcosa is raising $3,529,800.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Ridall played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orcosa
Orcosa Inc. is a life sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe) Platform. Founded in 2020, Orcosa is the inventor, developer and exclusive owner of the RITe Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosas first product candidate, ORAVEXX, is a non-addictive proprietary cannabidiol composition that utilizes the RITe Platform to treat moderate to severe pain and provide a safe, alternative treatment option to opioids.

To learn more about Orcosa, visit http://orcosa.com/

Contact:
Mark Ridall, Chief Executive Officer
609-583-5716
https://www.linkedin.com/in/mark-ridall-046121210/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved